Cargando…
MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses
In vitro neutralizing antibodies have been often correlated with protection against Rift Valley fever virus (RVFV) infection. We have reported previously that a single inoculation of sucrose-purified modified vaccinia Ankara (MVA) encoding RVFV glycoproteins (rMVAGnGc) was sufficient to induce a pro...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157666/ https://www.ncbi.nlm.nih.gov/pubmed/32059491 http://dx.doi.org/10.3390/vaccines8010082 |
_version_ | 1783522394483195904 |
---|---|
author | López-Gil, Elena Moreno, Sandra Ortego, Javier Borrego, Belén Lorenzo, Gema Brun, Alejandro |
author_facet | López-Gil, Elena Moreno, Sandra Ortego, Javier Borrego, Belén Lorenzo, Gema Brun, Alejandro |
author_sort | López-Gil, Elena |
collection | PubMed |
description | In vitro neutralizing antibodies have been often correlated with protection against Rift Valley fever virus (RVFV) infection. We have reported previously that a single inoculation of sucrose-purified modified vaccinia Ankara (MVA) encoding RVFV glycoproteins (rMVAGnGc) was sufficient to induce a protective immune response in mice after a lethal RVFV challenge. Protection was related to the presence of glycoprotein specific CD8+ cells, with a low-level detection of in vitro neutralizing antibodies. In this work we extended those observations aimed to explore the role of humoral responses after MVA vaccination and to study the contribution of each glycoprotein antigen to the protective efficacy. Thus, we tested the efficacy and immune responses in BALB/c mice of recombinant MVA viruses expressing either glycoprotein Gn (rMVAGn) or Gc (rMVAGc). In the absence of serum neutralizing antibodies, our data strongly suggest that protection of vaccinated mice upon the RVFV challenge can be achieved by the activation of cellular responses mainly directed against Gc epitopes. The involvement of cellular immunity was stressed by the fact that protection of mice was strain dependent. Furthermore, our data suggest that the rMVA based single dose vaccination elicits suboptimal humoral immune responses against Gn antigen since disease in mice was exacerbated upon virus challenge in the presence of rMVAGnGc or rMVAGn immune serum. Thus, Gc-specific cellular immunity could be an important component in the protection after the challenge observed in BALB/c mice, contributing to the elimination of infected cells reducing morbidity and mortality and counteracting the deleterious effect of a subneutralizing antibody immune response. |
format | Online Article Text |
id | pubmed-7157666 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71576662020-05-01 MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses López-Gil, Elena Moreno, Sandra Ortego, Javier Borrego, Belén Lorenzo, Gema Brun, Alejandro Vaccines (Basel) Article In vitro neutralizing antibodies have been often correlated with protection against Rift Valley fever virus (RVFV) infection. We have reported previously that a single inoculation of sucrose-purified modified vaccinia Ankara (MVA) encoding RVFV glycoproteins (rMVAGnGc) was sufficient to induce a protective immune response in mice after a lethal RVFV challenge. Protection was related to the presence of glycoprotein specific CD8+ cells, with a low-level detection of in vitro neutralizing antibodies. In this work we extended those observations aimed to explore the role of humoral responses after MVA vaccination and to study the contribution of each glycoprotein antigen to the protective efficacy. Thus, we tested the efficacy and immune responses in BALB/c mice of recombinant MVA viruses expressing either glycoprotein Gn (rMVAGn) or Gc (rMVAGc). In the absence of serum neutralizing antibodies, our data strongly suggest that protection of vaccinated mice upon the RVFV challenge can be achieved by the activation of cellular responses mainly directed against Gc epitopes. The involvement of cellular immunity was stressed by the fact that protection of mice was strain dependent. Furthermore, our data suggest that the rMVA based single dose vaccination elicits suboptimal humoral immune responses against Gn antigen since disease in mice was exacerbated upon virus challenge in the presence of rMVAGnGc or rMVAGn immune serum. Thus, Gc-specific cellular immunity could be an important component in the protection after the challenge observed in BALB/c mice, contributing to the elimination of infected cells reducing morbidity and mortality and counteracting the deleterious effect of a subneutralizing antibody immune response. MDPI 2020-02-12 /pmc/articles/PMC7157666/ /pubmed/32059491 http://dx.doi.org/10.3390/vaccines8010082 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article López-Gil, Elena Moreno, Sandra Ortego, Javier Borrego, Belén Lorenzo, Gema Brun, Alejandro MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses |
title | MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses |
title_full | MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses |
title_fullStr | MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses |
title_full_unstemmed | MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses |
title_short | MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses |
title_sort | mva vectored vaccines encoding rift valley fever virus glycoproteins protect mice against lethal challenge in the absence of neutralizing antibody responses |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157666/ https://www.ncbi.nlm.nih.gov/pubmed/32059491 http://dx.doi.org/10.3390/vaccines8010082 |
work_keys_str_mv | AT lopezgilelena mvavectoredvaccinesencodingriftvalleyfevervirusglycoproteinsprotectmiceagainstlethalchallengeintheabsenceofneutralizingantibodyresponses AT morenosandra mvavectoredvaccinesencodingriftvalleyfevervirusglycoproteinsprotectmiceagainstlethalchallengeintheabsenceofneutralizingantibodyresponses AT ortegojavier mvavectoredvaccinesencodingriftvalleyfevervirusglycoproteinsprotectmiceagainstlethalchallengeintheabsenceofneutralizingantibodyresponses AT borregobelen mvavectoredvaccinesencodingriftvalleyfevervirusglycoproteinsprotectmiceagainstlethalchallengeintheabsenceofneutralizingantibodyresponses AT lorenzogema mvavectoredvaccinesencodingriftvalleyfevervirusglycoproteinsprotectmiceagainstlethalchallengeintheabsenceofneutralizingantibodyresponses AT brunalejandro mvavectoredvaccinesencodingriftvalleyfevervirusglycoproteinsprotectmiceagainstlethalchallengeintheabsenceofneutralizingantibodyresponses |